Progenics Pharma Balance Sheet - Quarterly (NASDAQ:PGNX)

Add to My Stocks
$7.54 $0.82 (9.81%) PGNX stock closing price Mar 23, 2018 (Closing)

A thorough fundamental analysis involves using data from Progenics Pharma balance sheet, apart from other financial statements, to value the business. All three financial statements should be used to measure the financial performance of the company, and should form a part of the Progenics Pharma stock analysis. Quarterly results are typically accompanied with the company releasing financial statements. Progenics Pharma had a long term debt of $47.78M at the end of 2017 Q3. To understand the debt servicing capacity of the company, one needs to look at Progenics Pharma operating cash flow and Progenics Pharma revenue also. Progenics Pharma debt to equity ratio is 0.78.

View and download Progenics Pharma quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Marketable Securities---------
Raw Materials---------
Work In Progress---------
Finished Goods---------
Notes Receivable---------
Other Current Assets1.66M3.26M3.67M4.32M3.77M5.33M5.12M5.63M5.96M
Total Current Assets
Property Plant & Equipment---5.59M---12.67M-
Accumulated Depreciation-------10.27M-
Net Property Plant & Equipment
Investment & Advances---------
Other Non-Current Assets---------
Deferred Charges---------
Deposits & Other Assets2.47M2.47M2.47M2.47M2.71M1.69M1.69M1.69M-
Total Assets
Notes Payable---------
Accounts Payable1.11M1.13M--1.1M1.06M1.5M9.54M9.82M
Current Portion Long-Term Debt1.83M1.24M-------
Current Portion Capital Leases---------
Accrued Expenses10.1M14.1M12.7M15.76M12.69M12.05M9.74M--
Income Taxes Payable---------
Other Current Liabilities---------
Total Current Liabilities
Deferred Taxes/Income13.01M13.01M13.01M13.01M11.19M11.19M-11.19M11.33M
Convertible Debt---------
Long-Term Debt47.78M48.32M48.85M49.45M-----
Non-Current Capital Leases---------
Other Long-Term Liabilities18.94M18.16M17.38M15.4M20.88M19.73M31.17M19.66M18.97M
Total Liabilities
Minority Interest---------
Preferred Stock---------
Common Stock Net---------
Capital Surplus601.68M600.82M598.9M598.06M596.97M596.05M595.08M594.51M593.54M
Retained Earnings-538.92M-523.56M-506.93M-490.57M-483.36M-519.67M-514.03M-501.37M-494.23M
Treasury Stock2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M2.74M
Other Liabilities-0.03M-0.05M-0.06M-0.08M-----
Shareholders Equity60.08M74.55M89.25M104.76M111.03M73.83M78.49M90.66M96.66M
Total Liabilities & Shareholders Equity152.88M170.52M182.85M198.98M156.93M118.2M121.03M131.25M136.91M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the Progenics Pharma stock price, and Progenics Pharma historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Progenics Pharma PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Progenics Pharma owns and has monetary significance. PGNX assets decreased from $170.52M in 2017 Q2 to $152.88M in 2017 Q3. Assets can be of two types: fixed assets like real estate, plant and machinery; and current assets which includes cash, accounts receivable etc. Tech stocks typically don't have too many assets.
  • Liabilities include short term loans and long term loans availed by the company to fund its business operations. PGNX stock had total liabilities of $92.8M for the quarter 2017 Q3.

Progenics Pharma Balance Sheet - Key Ratios

Current ratio
Debt to equity ratio
Asset turnover ratio
Receivables turnover
Price to book ratio